KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) R&D In Process (2020 - 2025)

Pfizer (PFE) has disclosed R&D In Process for 8 consecutive years, with $212.0 million as the latest value for Q4 2025.

  • Quarterly R&D In Process changed N/A to $212.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $1.6 billion for FY2025, 1393.52% up from the prior year.
  • R&D In Process for Q4 2025 was $212.0 million at Pfizer, down from $1.4 billion in the prior quarter.
  • The five-year high for R&D In Process was $1.4 billion in Q3 2025, with the low at $1.0 million in Q3 2022.
  • Average R&D In Process over 5 years is $232.3 million, with a median of $67.0 million recorded in 2023.
  • The sharpest move saw R&D In Process crashed 99.54% in 2022, then soared 10592.31% in 2025.
  • Over 5 years, R&D In Process stood at $300.0 million in 2021, then surged by 74.67% to $524.0 million in 2022, then tumbled by 86.26% to $72.0 million in 2023, then tumbled by 81.94% to $13.0 million in 2024, then skyrocketed by 1530.77% to $212.0 million in 2025.
  • According to Business Quant data, R&D In Process over the past three periods came in at $212.0 million, $1.4 billion, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.